Compare BridgeBio Pharma Inc (BBIO) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Fastly Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Fastly Inc trades at $28.6 (market cap $4.42B). The key difference: BridgeBio Pharma Inc is far larger — about 3.8× Fastly Inc's market cap. Which is the better fit depends on your goals.
| BBIO | FSLY | |
|---|---|---|
Market Cap | $16.61B | $4.42B |
Sector | Health | Technology |
52-Week High | $90.17 | $33.50 |
52-Week Low | $47.29 | $6.85 |
Enterprise Value | $18.16B | $4.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Fastly (FSLY) trades at $22.96, up 1.23% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $624 million in 2025, and the net loss margin improved to -19.5%. Recent news highlights security expansion and AI demand driving growth, with the stock surging 21% to $27.69 on August 10, 2026, per 24/7 Wall Street. The company raised its full-year 2026 outlook after Q2 results.
The outlook is positive with raised guidance and analyst consensus target of $28.25, but risks include persistent net losses, high debt, and competitive pressure. Investment opportunity lies in AI and security growth, yet profitability challenges and insider selling warrant caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
